Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Philip Newsome, Sven Francque, Stephen Harrison and 6 more

Alimentary Pharmacology & Therapeutics · 2019 · CC BY

doi:10.1111/apt.15316

Abstract

Background. Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment.

Aim. To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglutide, on alanine aminotransferase (ALT) and high‐sensitivity C‐reactive protein (hsCRP) in subjects at risk of NAFLD.

Methods. Data from a 104‐week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52‐week weight management trial (semaglutide 0.05‐0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight.

Results. Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end‐of‐treatment ALT reductions were 6%‐21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%‐43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%‐46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end‐of‐treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change.

Conclusions. Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.

References 59

  1. 1.

    Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686‐690.

    Not in our library10.1038/nrgastro.2013.171

  2. 2.

    Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64:1969‐1977.

    Not in our library10.1002/hep.28677

  3. 3.

    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73‐84.

    Not in our library10.1002/hep.28431

  4. 4.

    Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844‐1850.

    Not in our library10.2337/diabetes.50.8.1844

  5. 5.

    Wang Y, Li YY, Nie YQ, Zhou YJ, Cao CY, Xu L. Association between metabolic syndrome and the development of non‐alcoholic fatty liver disease. Exp Ther Med. 2013;6:77‐84.

    Not in our library10.3892/etm.2013.1090

  6. 6.

    Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non‐alcoholic fatty liver disease. Dig Dis. 2010;28:155‐161.

    Not in our library10.1159/000282080

  7. 7.

    Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134‐140.

    Not in our library10.1053/gast.2002.34168

  8. 8.

    Ekstedt M, Franzén LE, Mathiesen UL, et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865‐873.

    Not in our library10.1002/hep.21327

  9. 9.

    Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology. 2015;61:1547‐1554.

    Not in our library10.1002/hep.27368

  10. 10.

    Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy‐proven NAFLD. J Hepatol. 2017;67:1265‐1273.

    Not in our library10.1016/j.jhep.2017.07.027

  11. 11.

    Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357‐1365.

    Not in our library10.1002/hep.26156

  12. 12.

    Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174‐1197.

    Not in our library10.1002/hep.26717

  13. 13.

    Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547‐555.

    Not in our library10.1053/j.gastro.2014.11.039

  14. 14.

    Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649‐1659.

    Not in our library10.1038/s41395-018-0088-6

  15. 15.

    Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2018, doi: 10.1016/j.cgh.2018.05.057 [Epub ahead of print].

    Not in our library10.1016/j.cgh.2018.05.057

  16. 16.
    Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control · 2016
    No notice
  17. 17.

    Sun F, Wu S, Wang J, et al. Effect of glucagon‐like peptide‐1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta‐analysis. Clin Ther. 2015;37:225‐241.e8.

    Not in our library10.1016/j.clinthera.2014.11.008

  18. 18.

    Katout M, Zhu H, Rutsky J, et al. Effect of GLP‐1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta‐analysis and meta‐regression. Am J Hypertens. 2014;27:130‐139.

    Not in our library10.1093/ajh/hpt196

  19. 19.

    Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311‐322.

    Not in our library10.1056/nejmoa1603827

  20. 20.

    Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834‐1844.

    Not in our library10.1056/nejmoa1607141

  21. 21.

    Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double‐blind, randomised placebo‐controlled trial. Lancet. 2018;392:1519‐1529.

    Not in our library10.1016/s0140-6736(18)32261-x

  22. 22.

    Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program. Aliment Pharmacol Ther. 2013;37:234‐242.

    Not in our library10.1111/apt.12149

  23. 23.

    Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non‐alcoholic steatohepatitis (LEAN): a multicentre, double‐blind, randomised, placebo‐controlled phase 2 study. Lancet. 2016;387:679‐690.

    Not in our library10.1016/s0140-6736(15)00803-x

  24. 24.

    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960‐967.

    Not in our library10.1111/j.1572-0241.2003.07486.x

  25. 25.

    Portillo‐Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100:2231‐2238.

    Not in our library10.1210/jc.2015-1966

  26. 26.

    Yoneda M, Mawatari H, Fujita K, et al. High‐sensitivity C‐reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42:573‐582.

    Not in our library10.1007/s00535-007-2060-x

  27. 27.

    Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134‐143.

    Not in our library10.1111/apt.12352

  28. 28.

    O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double‐blind, placebo and active controlled, dose‐ranging, phase 2 trial. Lancet. 2018;392:637‐649.

    Not in our library10.1016/s0140-6736(18)31773-2

  29. 29.

    Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846‐854.

    Not in our library10.1002/hep.21496

  30. 30.

    Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317‐1325.

    Not in our library10.1002/hep.21178

  31. 31.

    Vallet‐Pichard A, Mallet V, Nalpas B, et al. FIB‐4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32‐36.

    Not in our library10.1002/hep.21669

  32. 32.

    McPherson S, Hardy T, Dufour J‐F, et al. Age as a confounding factor for the accurate non‐invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112:740‐751.

    Not in our library10.1038/ajg.2016.453

  33. 33.

    Alberti K, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640‐1645.

    Not in our library10.1161/circulationaha.109.192644

  34. 34.

    Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:193‐10.

    Not in our library10.7326/0003-4819-137-1-200207020-00006

  35. 35.

    Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non‐alcoholic fatty liver disease. QJM. 2010;103:71‐83.

    Not in our library10.1093/qjmed/hcp158

  36. 36.

    Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181‐205.

    Not in our library10.1146/annurev-physiol-021115-105331

  37. 37.

    Kalra S, Gupta Y. Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA). J Pak Med Assoc. 2016;66:357‐359.

    Not in our library

  38. 38.

    Li S, Wang X, Zhang J, et al. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. Braz J Med Biol Res. 2018;51:e7299.

    Not in our library10.1590/1414-431x20187299

  39. 39.

    Rahman K, Liu Y, Kumar P, et al. C/EBP homologous protein modulates liraglutide‐mediated attenuation of non‐alcoholic steatohepatitis. Lab Invest. 2016;96:895‐908.

    Not in our library10.1038/labinvest.2016.61

  40. 40.
    Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice · 2012
    No notice
  41. 41.

    Dhir G, Cusi K. Glucagon like peptide‐1 receptor agonists for the management of obesity and non‐alcoholic fatty liver disease: a novel therapeutic option. J Investig Med. 2018;66:7‐10.

    Not in our library10.1136/jim-2017-000554

  42. 42.

    Geloneze B, de Lima‐Junior JC, Velloso LA. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in the brain‐adipocyte axis. Drugs. 2017;77:493‐503.

    Not in our library10.1007/s40265-017-0706-4

  43. 43.

    Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722‐728.

    Not in our library10.7326/0003-4819-143-10-200511150-00009

  44. 44.

    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917‐923.

    Not in our library10.1053/jhep.2003.50161

  45. 45.

    Neuschwander‐Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial. Lancet. 2015;385:956‐965.

    Not in our library10.1016/s0140-6736(14)61933-4

  46. 46.

    Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator‐activated receptor‐alpha and ‐delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147–1159:e5.

    Not in our library10.1053/j.gastro.2016.01.038

  47. 47.

    Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E‐LIFT Trial). Diabetes Care. 2018;41:1801–1808.

    Not in our library10.2337/dc18-0165

  48. 48.

    Ratziu V, Harrison SA, Francque S, et al. ALT as a non‐invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial. Hepatology. 2016;64(suppl. 1):581A–582A.

    Not in our library

  49. 49.

    Loomba R, Sanyal AJ, Kowdley KV, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology. 2018;156: 88–95.e5.

    Not in our library10.1053/j.gastro.2018.09.021

  50. 50.

    Vilar‐Gomez E, Calzadilla‐Bertot L, Friedman SL, et al. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASH. Liver Int. 2017;37:1887–1896.

    Not in our library10.1111/liv.13480

  51. 51.

    Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C‐reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334.

    Not in our library10.1001/jama.286.3.327

  52. 52.

    Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C‐reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–1320.

    Not in our library10.1056/nejmoa1107477

  53. 53.

    Lee J, Yoon K, Ryu S, Chang Y, Kim HR. High‐normal levels of hs‐CRP predict the development of non‐alcoholic fatty liver in healthy men. PLoS ONE. 2017;12:e0172666.

    Not in our library10.1371/journal.pone.0172666

  54. 54.

    Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High‐sensitivity C‐reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol. 2009;44:313–321.

    Not in our library10.1007/s00535-009-0002-5

  55. 55.

    Yeniova AO, Kucukazman M, Ata N, et al. High‐sensitivity C‐reactive protein is a strong predictor of non‐alcoholic fatty liver disease. Hepatogastroenterology. 2014;61:422–425.

    Not in our library

  56. 56.

    Zimmermann E, Anty R, Tordjman J, et al. C‐reactive protein levels in relation to various features of non‐alcoholic fatty liver disease among obese patients. J Hepatol. 2011;55:660–665.

    Not in our library10.1016/j.jhep.2010.12.017

  57. 57.

    Maleki I, Rastgar A, Hosseini V, et al. High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2014;18:1583–1590.

    Not in our library

  58. 58.

    Bi Y, Min M, Shen W, et al. Prognostic value of high sensitivity C‐reaction protein in non‐insulin dependent diabetes mellitus patients with non‐alcoholic fatty liver disease. Int J Clin Exp Pathol. 2015;8:8494–8499.

    Not in our library

  59. 59.

    Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67:1754–1767.

    Not in our library10.1002/hep.29477

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.